At a glance
ClinicalIndex Comparison RecordPhase 3Completed· 486 enrolled
Drug / intervention
Ceftazidime-avibactam +2 moredrug
Likely dose
Ceftazidime-avibactam 2000 mgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Phase III, Randomized, Multicenter, Double Blind, Double-Dummy, Parallel-Group, Comparative Study to Determine the Efficacy, Safety, and Tolerability of Ceftazidime Avibactam Plus Metronidazole Versus Meropenem in the Treatment of Complicated Intra-Abdominal Infections In Hospitalized Adults
In Brief
A Phase 3 clinical trial evaluating Ceftazidime-avibactam, metronidazole, and 1 other intervention for Complicated Intra-abdominal Infection. Completed, enrolled 486 participants across 30 sites in 3 countries.
Detailed Summary
The purpose of this study is to evaluate the effects of Ceftazidime Avibactam plus Metronidazole compared to Meropenem for treating hospitalized patients with complicated intra-abdominal infections.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsComplicated Intra-abdominal Infection
CountriesChina, South Korea, Vietnam
Collaborators--
Timeline
Phase 3CompletedFinished
20132014201520162017201820192020202120222023202420252026
First PostedNov 2012
Enrollment StartJan 2013
Primary CompletionMar 2015
TodayJul 2026
First PostedNov 14, 2012
Enrollment StartJan 1, 2013
Primary CompletionMar 1, 2015
TodayJul 2, 2026
Enrollment to primary: 2.2 yearsPosted 13.6 years ago
Interventions
Ceftazidime-avibactamdrug
Ceftazidime-Avibactam powder for concentrate for solution for infusion 2000 mg/500 mg
metronidazoledrug
Metronidazole 500mg/100ml solution for infusion
Meropenemdrug
Meropenem powder for solution for infusion 1000mg